EQS-News

CompuGroup Medical SE & Co. KGaA: CGM in 2022 with double-digit revenue growth – strong 2023 guidance underlines mid-term ambitions - Seite 3

Guidance for 2023

CompuGroup Medical expects a year with swift execution on numerous digitization projects and attractive organic growth driven by the investment initiative. For 2023, the company anticipates group revenues to grow by around 5 % organically. CGM expects an adjusted EBITDA in the range of EUR 260 million to EUR 300 million.

Development 2022: All segments delivered growth in 2022

In 2022, revenues in the Ambulatory Information Systems segment rose by 6 % to EUR 502 million (previous year: EUR 476 million). Organically, revenues grew by 1 % against a strong prior year with additional rollouts of new modules like the e-health record and vaccination certificates in the DACH region during H2 2021. Recurring revenues amounted to 77 % of segment revenues, representing 7 % growth compared to the previous year, underlining the continued strength of the segment. For 2023, CGM expects organic revenue growth in the mid-single digit percentage area.

In the Hospital Information Systems segment, revenues increased by 8 % to EUR 277 million (previous year: EUR 257 million) in 2022.  Organic growth stood at 3 %, against higher prior year comps. In addition to continued demand for innovative technologies like the G3 platform, CGM recorded great business progress in Spain and Poland. Recurring revenues grew by 15 % leading to a share of 69 % compared to total revenues. For 2023, CGM expects organic revenue growth in the mid- to high-single digit percentage area.

Again, a strong development has been recorded in the Consumer & Health Management Information Systems segment, where revenues increased by 26 % to EUR 220 million, representing an organic growth of 12 % compared to 2021. Adjusted for TI, organic revenues grew 4 %, impacted by macro-crisis-related headwinds in the pharma industry. Recurring revenues rose by 13 % resulting in a share of recurring revenues of 32 %. For CHS, organic revenue growth is expected in a low- to mid-single digit percentage area for 2023.